Reuters Photojournalism
Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography. See more | Photo caption
The Afghan Army
The many faces of the Afghan National Army, which has taken over security of the country from NATO. Slideshow
Sponsored Links
UK's NICE rejects Novartis asthma drug in change of tack
LONDON |
LONDON (Reuters) - Britain's health cost-effectiveness watchdog NICE plans to recommend against the use of Novartis's severe asthma drug Xolair, or omalizumab, after earlier endorsing it for adults only.
The National Institute for Health and Clinical Excellence (NICE), which decides if medicines should be given on the state health service, said on Friday it had changed its mind in the light of evolving clinical evidence.
"After considering new evidence that has become available since the original guidance was published - particularly new mortality data - the NICE draft guidance does not recommend omalizumab for either adults or children," NICE said.
New dosing recommendations for the drug had also changed its cost-effectiveness, the agency added.
The revised recommendation against using the drug is still at the review stage and NICE said it was now up to Novartis and other interested parties to respond to its concerns.
(Reporting by Ben Hirschler; Editing by Elaine Hardcastle)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters